...
zvsa-img

ZyVersa Therapeutics Inc., Common Stock

ZVSA

NAQ

$1.235

+$0.14

(12.73%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.36M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0.002
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.15M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.64
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.98 L
$13.4 H
$1.235

About ZyVersa Therapeutics Inc., Common Stock

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameZVSASectorS&P500
1-Week Return-1.79%-3.39%-3.47%
1-Month Return-11.29%-3.25%-0.29%
3-Month Return-54.73%-11.61%4.5%
6-Month Return-78.22%-5.89%6.91%
1-Year Return-89.72%2.65%23.79%
3-Year Return3042.86%0.56%28.43%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue10.40K10.40K10.40K10.40K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(10.40K)(10.40K)(10.40K)(10.40K)[{"date":"2020-12-31","value":-1040000,"profit":false},{"date":"2021-12-31","value":-1040000,"profit":false},{"date":"2022-12-31","value":-1040000,"profit":false},{"date":"2023-12-31","value":-1040000,"profit":false}]
Gross Margin----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses11.83M7.70M13.01M14.41M[{"date":"2020-12-31","value":82.11,"profit":true},{"date":"2021-12-31","value":53.46,"profit":true},{"date":"2022-12-31","value":90.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(11.83M)(7.70M)(13.01M)(14.42M)[{"date":"2020-12-31","value":-1183305800,"profit":false},{"date":"2021-12-31","value":-770437600,"profit":false},{"date":"2022-12-31","value":-1301306400,"profit":false},{"date":"2023-12-31","value":-1442077400,"profit":false}]
Total Non-Operating Income/Expense(1.37M)(1.20M)(2.79M)(93.38M)[{"date":"2020-12-31","value":-136655800,"profit":false},{"date":"2021-12-31","value":-120115100,"profit":false},{"date":"2022-12-31","value":-279301700,"profit":false},{"date":"2023-12-31","value":-9338216900,"profit":false}]
Pre-Tax Income(12.68M)(8.08M)(14.05M)(107.75M)[{"date":"2020-12-31","value":-1268316600,"profit":false},{"date":"2021-12-31","value":-808416100,"profit":false},{"date":"2022-12-31","value":-1404760700,"profit":false},{"date":"2023-12-31","value":-10775377600,"profit":false}]
Income Taxes516.45K821.37K745.05M(9.46M)[{"date":"2020-12-31","value":0.07,"profit":true},{"date":"2021-12-31","value":0.11,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1.27,"profit":false}]
Income After Taxes(13.20M)(8.91M)(759.10M)(98.30M)[{"date":"2020-12-31","value":-1319961600,"profit":false},{"date":"2021-12-31","value":-890552700,"profit":false},{"date":"2022-12-31","value":-75909760700,"profit":false},{"date":"2023-12-31","value":-9829794600,"profit":false}]
Income From Continuous Operations(12.68M)(8.08M)(14.05M)(89.56M)[{"date":"2020-12-31","value":-1268316600,"profit":false},{"date":"2021-12-31","value":-808416100,"profit":false},{"date":"2022-12-31","value":-1404760700,"profit":false},{"date":"2023-12-31","value":-8956172800,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(13.20M)(8.91M)(759.10M)(98.30M)[{"date":"2020-12-31","value":-1319961600,"profit":false},{"date":"2021-12-31","value":-890552700,"profit":false},{"date":"2022-12-31","value":-75909760700,"profit":false},{"date":"2023-12-31","value":-9829794600,"profit":false}]
EPS (Diluted)--(180.38)(19.12)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-18038.42,"profit":false},{"date":"2023-12-31","value":-1912.04,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ZVSA
Cash Ratio 10.65
Current Ratio 33.83

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ZVSA
ROA (LTM) -24.92%
ROE (LTM) -152.23%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ZVSA
Debt Ratio Lower is generally better. Negative is bad. 0.64
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.36

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ZVSA
Trailing PE 0.00
Forward PE NM
P/S (TTM) 0.00
P/B 0.34
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is ZyVersa Therapeutics Inc. share price today?

ZyVersa Therapeutics Inc. (ZVSA) share price today is $1.235

Can Indians buy ZyVersa Therapeutics Inc. shares?

Yes, Indians can buy shares of ZyVersa Therapeutics Inc. (ZVSA) on Vested. To buy ZyVersa Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZVSA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of ZyVersa Therapeutics Inc. be purchased?

Yes, you can purchase fractional shares of ZyVersa Therapeutics Inc. (ZVSA) via the Vested app. You can start investing in ZyVersa Therapeutics Inc. (ZVSA) with a minimum investment of $1.

How to invest in ZyVersa Therapeutics Inc. shares from India?

You can invest in shares of ZyVersa Therapeutics Inc. (ZVSA) via Vested in three simple steps:

  • Click on Sign Up or Invest in ZVSA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in ZyVersa Therapeutics Inc. shares
What is ZyVersa Therapeutics Inc. 52-week high and low stock price?

The 52-week high price of ZyVersa Therapeutics Inc. (ZVSA) is $13.4. The 52-week low price of ZyVersa Therapeutics Inc. (ZVSA) is $0.98.

What is ZyVersa Therapeutics Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of ZyVersa Therapeutics Inc. (ZVSA) is 0.002

What is ZyVersa Therapeutics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of ZyVersa Therapeutics Inc. (ZVSA) is 0.34

What is ZyVersa Therapeutics Inc. dividend yield?

The dividend yield of ZyVersa Therapeutics Inc. (ZVSA) is 0.00%

What is the Market Cap of ZyVersa Therapeutics Inc.?

The market capitalization of ZyVersa Therapeutics Inc. (ZVSA) is $2.36M

What is ZyVersa Therapeutics Inc.’s stock symbol?

The stock symbol (or ticker) of ZyVersa Therapeutics Inc. is ZVSA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top